Cellectar Biosciences Inc CLRB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CLRB is a good fit for your portfolio.
News
-
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
-
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
-
Cellectar Biosciences to Present at the 36th Annual Roth Conference
-
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
-
Thinking about buying stock in TOP Financial Group, Macy's, MicroCloud Hologram, Cellectar Biosciences, or New York Community Bancorp?
-
Thinking about buying stock in Plug Power, Confluent, Cellectar Biosciences, Bakkt Holdings, or Digital Turbine?
-
Thinking about buying stock in Cellectar Biosciences, elf Beauty, Glatfelter, Solidion Technology, or Spectral AI?
-
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Trading Information
- Previous Close Price
- $3.05
- Day Range
- $2.95–3.10
- 52-Week Range
- $1.35–4.45
- Bid/Ask
- $3.03 / $3.05
- Market Cap
- $98.56 Mil
- Volume/Avg
- 541,078 / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 20
- Website
- https://www.cellectar.com
Valuation
Metric
|
CLRB
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CLRB
Financial Strength
Metric
|
CLRB
|
---|---|
Quick Ratio | 0.74 |
Current Ratio | 0.81 |
Interest Coverage | — |
Quick Ratio
CLRB
Profitability
Metric
|
CLRB
|
---|---|
Return on Assets (Normalized) | −238.86% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −1,747.48% |
Return on Assets
CLRB
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Sxptjwnnx | Fxry | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kkvbrgc | Nhsdkk | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zxfxvcb | Gjgyfx | $99.5 Bil | |
MRNA
| Moderna Inc | Mdgwrzdvs | Whdbt | $38.8 Bil | |
ARGX
| argenx SE ADR | Wdfpnrqxt | Xpfh | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Wvxggybx | Yps | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zkqnnmwr | Sldntl | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vmwzvkfb | Qdtcfr | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zqxxjztyr | Bsvbsgn | $12.5 Bil | |
INCY
| Incyte Corp | Tbzkqjql | Njgrj | $11.6 Bil |